Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on a staff interview, record review, and a review of the facility's policies and procedures, the facility failed to update a resident's Pre-admission Screening and Resident Review (PASRR) to include the resident's mental illness diagnosis for one (Resident #11) of two residents reviewed for PASRR completion from a total survey sample of 31 residents.
The findings include:
A review of the medical record revealed that Resident #11 was admitted to the facility on [DATE] with diagnoses including schizoaffective disorder - bipolar type and unspecified mood [affective] disorder.
On 5/13/2025 at 11:09 AM, further review of the record revealed a PASRR completed on 7/11/2020 that did not document the resident's mental illness diagnoses of schizoaffective disorder - bipolar type, or unspecified mood [affective] disorder.
A review of the resident's Annual minimum data set (MDS) assessment with an assessment reference date (ARD) of 11/4/2024, revealed that the resident was diagnosed with epilepsy or seizure disorder, schizophrenia, multiple sclerosis, and unspecified mood [affective] disorder. Section N of the MDS indicated that the resident received antipsychotic and anticonvulsant medications during the 7-day assessment period.
Further review of the record revealed that Resident #11 had active physician's orders for the following:
Divalproex Sodium Oral Tablet Delayed Release 500 mg (milligrams), Give 1 tablet by mouth every morning and at bedtime for mood disorder (4/28/2023)
Divalproex Sodium Oral Tablet Delayed Release 250 mg, Give 1 tablet by mouth at bedtime for mood disorder. Give with 500 mg dose for total dose of 750 mg (10/4/24)
Risperdal Oral Tablet 2 mg, Give 2 mg by mouth one time a day for schizoaffective disorder, and give 4 mg by mouth at bedtime for schizoaffective disorder (2/25/25).
Observe closely for side effects of antipsychotic medication including dry mouth, constipation, blurred vision, disorientation or confusion, difficulty urinating, hypotension, dark urine, yellow skin, nausea or vomiting, lethargy, drooling, extrapyramidal symptoms (tremors, disturbed gait, increased agitation, restlessness, involuntary movement of mouth or tongue) every shift (9/6/23)
Observe closely for significant side effects of sedative/hypnotic medication including burning or tingling in hands or feet, changes in appetite, constipation, diarrhea, dizziness, drowsiness, dry mouth or throat, headache, stomach complaints, tremors, weakness every shift (9/6/2023)
Psychiatric consult as needed (10/16/23)
Observe closely for significant side effects of anti-depressant medication including drowsiness, blurred vision, dizziness, nausea, fatigue, trouble sleeping, dry mouth, hallucinations, other unusual changes in mood or behavior every shift (2/27/2025)
Monitor for the following behaviors: yelling, mood changes, sleeplessness, hallucinations, delirium every shift (3/6/2025)
A review of the resident's active care plan revealed the following focus area:
[Resident #11] receives antipsychotic medication related to diagnosis of schizoaffective disorder - bipolar type and psychosis (created 4/19/23, revised 5/13/24). Goals/Interventions in place.
A review of the Psychiatric Evaluation progress note with date of service 10/6/23 revealed that the diagnoses of bipolar disorder, current episode mixed, severe, with psychotic features; generalized anxiety and insomnia. The note also documented instructions to Please update diagnoses accordingly.
On 5/15/2025 at 12:38 PM, an interview was conducted with the Business Office Manager (BOM) who stated she had been in her current position for 6 to 7 months. Further, she had been employed by the facility for seven years. She stated she was responsible for ensuring PASRRs were current and in each resident's EMR. When asked how she would determine whether or not a PASRR was accurate, she replied, I would look at the diagnoses and make sure it (the PASRR) is filled out properly. If it was not filled out properly, she stated she would correct it. If a PASRR indicated that a level II screening was needed, she would verify the information was correct, gather any further information needed, and submit that to the State Mental Health/Intellectual Disability Authority's website.
A review of the facility's policy titled Coordination-Pre-admission Screening and Resident Review (PASRR) Program (effective date: 1/14/2025), revealed:
It is the policy of the facility to assure that all residents admitted to the facility receive a Pre-admission Screening and Resident Review, in accordance with State and Federal Regulations.
Procedure:
3. Coordination includes a preadmission screening for individuals with a mental disorder and individuals with an intellectual disability.
5. A nursing facility must notify the state mental health authority or state intellectual disability authority, as applicable, promptly after a significant change in mental or physical condition of a resident who has mental illness or intellectual disability for resident review.
.
The findings include:
A review of the medical record revealed that Resident #11 was admitted to the facility on [DATE] with diagnoses including schizoaffective disorder - bipolar type and unspecified mood [affective] disorder.
On 5/13/2025 at 11:09 AM, further review of the record revealed a PASRR completed on 7/11/2020 that did not document the resident's mental illness diagnoses of schizoaffective disorder - bipolar type, or unspecified mood [affective] disorder.
A review of the resident's Annual minimum data set (MDS) assessment with an assessment reference date (ARD) of 11/4/2024, revealed that the resident was diagnosed with epilepsy or seizure disorder, schizophrenia, multiple sclerosis, and unspecified mood [affective] disorder. Section N of the MDS indicated that the resident received antipsychotic and anticonvulsant medications during the 7-day assessment period.
Further review of the record revealed that Resident #11 had active physician's orders for the following:
Divalproex Sodium Oral Tablet Delayed Release 500 mg (milligrams), Give 1 tablet by mouth every morning and at bedtime for mood disorder (4/28/2023)
Divalproex Sodium Oral Tablet Delayed Release 250 mg, Give 1 tablet by mouth at bedtime for mood disorder. Give with 500 mg dose for total dose of 750 mg (10/4/24)
Risperdal Oral Tablet 2 mg, Give 2 mg by mouth one time a day for schizoaffective disorder, and give 4 mg by mouth at bedtime for schizoaffective disorder (2/25/25).
Observe closely for side effects of antipsychotic medication including dry mouth, constipation, blurred vision, disorientation or confusion, difficulty urinating, hypotension, dark urine, yellow skin, nausea or vomiting, lethargy, drooling, extrapyramidal symptoms (tremors, disturbed gait, increased agitation, restlessness, involuntary movement of mouth or tongue) every shift (9/6/23)
Observe closely for significant side effects of sedative/hypnotic medication including burning or tingling in hands or feet, changes in appetite, constipation, diarrhea, dizziness, drowsiness, dry mouth or throat, headache, stomach complaints, tremors, weakness every shift (9/6/2023)
Psychiatric consult as needed (10/16/23)
Observe closely for significant side effects of anti-depressant medication including drowsiness, blurred vision, dizziness, nausea, fatigue, trouble sleeping, dry mouth, hallucinations, other unusual changes in mood or behavior every shift (2/27/2025)
Monitor for the following behaviors: yelling, mood changes, sleeplessness, hallucinations, delirium every shift (3/6/2025)
A review of the resident's active care plan revealed the following focus area:
[Resident #11] receives antipsychotic medication related to diagnosis of schizoaffective disorder - bipolar type and psychosis (created 4/19/23, revised 5/13/24). Goals/Interventions in place.
A review of the Psychiatric Evaluation progress note with date of service 10/6/23 revealed that the diagnoses of bipolar disorder, current episode mixed, severe, with psychotic features; generalized anxiety and insomnia. The note also documented instructions to Please update diagnoses accordingly.
On 5/15/2025 at 12:38 PM, an interview was conducted with the Business Office Manager (BOM) who stated she had been in her current position for 6 to 7 months. Further, she had been employed by the facility for seven years. She stated she was responsible for ensuring PASRRs were current and in each resident's EMR. When asked how she would determine whether or not a PASRR was accurate, she replied, I would look at the diagnoses and make sure it (the PASRR) is filled out properly. If it was not filled out properly, she stated she would correct it. If a PASRR indicated that a level II screening was needed, she would verify the information was correct, gather any further information needed, and submit that to the State Mental Health/Intellectual Disability Authority's website.
A review of the facility's policy titled Coordination-Pre-admission Screening and Resident Review (PASRR) Program (effective date: 1/14/2025), revealed:
It is the policy of the facility to assure that all residents admitted to the facility receive a Pre-admission Screening and Resident Review, in accordance with State and Federal Regulations.
Procedure:
3. Coordination includes a preadmission screening for individuals with a mental disorder and individuals with an intellectual disability.
5. A nursing facility must notify the state mental health authority or state intellectual disability authority, as applicable, promptly after a significant change in mental or physical condition of a resident who has mental illness or intellectual disability for resident review.
.